CG Oncology grants 107,508 options to COO Ambaw
CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CG Oncology, Inc. reported that President and COO Bellete Ambaw received a grant of employee stock options. The award covers 107,508 options to buy common stock at an exercise price of $67.68 per share, expiring on April 14, 2036.
According to the footnote, 1/48th of the options vest monthly after the April 15, 2026 vesting commencement date, contingent on Ambaw’s continuous service. Following this grant, Ambaw directly holds 107,508 derivative securities linked to CG Oncology common stock.
Insider Trade Summary
Grant/Award: 107,508 shares
Grant/Award
1 txn
Insider
Bellete Ambaw
Role
President and COO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) | 107,508 | $0.00 | $0.00 |
Holdings After Transaction:
Employee Stock Option (Right to Buy) — 107,508 contracts (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to the option vest monthly following April 15, 2026, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Key Figures
Options granted: 107,508 options
Exercise price: $67.68 per share
Underlying shares: 107,508 shares
+2 more
5 metrics
Options granted
107,508 options
Employee stock option grant to President and COO Bellete Ambaw
Exercise price
$67.68 per share
Conversion or exercise price for the employee stock options
Underlying shares
107,508 shares
Underlying CG Oncology common stock linked to the options
Expiration date
April 14, 2036
Option expiration for the granted employee stock options
Post-grant derivative holdings
107,508 derivative securities
Total options held directly after the reported transaction
Key Terms
Employee Stock Option (Right to Buy), exercise price, vesting commencement date, derivative securities
4 terms
Employee Stock Option (Right to Buy) financial
"security_title: Employee Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 67.6800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting commencement date financial
"vesting commencement date, subject to the Reporting Person's continuous service"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
derivative securities financial
"total_shares_following_transaction: 107508.0000"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CGON executive Bellete Ambaw report in this Form 4 filing?
Bellete Ambaw reported receiving an employee stock option grant. The award covers 107,508 options to buy CG Oncology common stock as part of compensation, recorded as an acquisition rather than an open-market purchase or sale.
How many CGON options did Bellete Ambaw receive and at what exercise price?
Bellete Ambaw received 107,508 employee stock options. Each option allows the purchase of one share of CG Oncology common stock at an exercise price of $67.68 per share, providing potential future ownership if exercised.
What is the vesting schedule for Bellete Ambaw’s CGON stock options?
The options vest gradually over time. The filing states that 1/48th of the shares subject to the option vest monthly after April 15, 2026, and vesting continues only while Ambaw maintains continuous service with CG Oncology.
When do Bellete Ambaw’s CGON stock options expire?
The options have a long-dated term. According to the filing, they expire on April 14, 2036, giving Ambaw a multi-year window after vesting to decide whether and when to exercise the options.
How many derivative securities does Bellete Ambaw hold after this CGON grant?
After this transaction, Ambaw directly holds 107,508 derivative securities. These represent the employee stock options granted in the filing, each tied to one underlying share of CG Oncology common stock, subject to vesting and future exercise decisions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates